223 related articles for article (PubMed ID: 36159870)
21. Impact of the Gut Microbiome on the Progression of Hepatitis B Virus Related Acute-on-Chronic Liver Failure.
Yao X; Yu H; Fan G; Xiang H; Long L; Xu H; Wu Z; Chen M; Xi W; Gao Z; Liu C; Gong W; Yang A; Sun K; Yu R; Liang J; Xie B; Sun S
Front Cell Infect Microbiol; 2021; 11():573923. PubMed ID: 33889550
[TBL] [Abstract][Full Text] [Related]
22. Outcome of laparoscopic splenectomy with sandwich treatment including pericardial devascularization and limited portacaval shunt for portal hypertension due to liver cirrhosis.
Zhao S; Lv T; Gong G; Wang C; Huang B; Zhou W
J Laparoendosc Adv Surg Tech A; 2013 Jan; 23(1):43-7. PubMed ID: 23248978
[TBL] [Abstract][Full Text] [Related]
23. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients.
Lu H; Wu Z; Xu W; Yang J; Chen Y; Li L
Microb Ecol; 2011 Apr; 61(3):693-703. PubMed ID: 21286703
[TBL] [Abstract][Full Text] [Related]
24. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation.
Nicoletti A; Ponziani FR; Biolato M; Valenza V; Marrone G; Sganga G; Gasbarrini A; Miele L; Grieco A
World J Gastroenterol; 2019 Sep; 25(33):4814-4834. PubMed ID: 31543676
[TBL] [Abstract][Full Text] [Related]
25. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis.
Bajaj JS; Vargas HE; Reddy KR; Lai JC; O'Leary JG; Tandon P; Wong F; Mitrani R; White MB; Kelly M; Fagan A; Patil R; Sait S; Sikaroodi M; Thacker LR; Gillevet PM
Clin Gastroenterol Hepatol; 2019 Mar; 17(4):756-765.e3. PubMed ID: 30036646
[TBL] [Abstract][Full Text] [Related]
26. A novel method detecting the key clinic factors of portal vein system thrombosis of splenectomy & cardia devascularization patients for cirrhosis & portal hypertension.
Wang M; Ding L; Xu M; Xie J; Wu S; Xu S; Yao Y; Liu Q
BMC Bioinformatics; 2019 Dec; 20(Suppl 22):720. PubMed ID: 31888439
[TBL] [Abstract][Full Text] [Related]
27. [Preoperative risk factors of portal venous thrombosis after splenectomy and gastric pericardial devascularization for portal hypertension].
Han J; Yi Y; Ding H; Liu J; Zhang Y; Hu L; Zhao L; Liu T
Zhonghua Gan Zang Bing Za Zhi; 2014 Oct; 22(10):739-43. PubMed ID: 25496862
[TBL] [Abstract][Full Text] [Related]
28. [Pericardial devascularization with splenectomy for the treatment of portal hypertension].
Yang Z; Qiu F
Zhonghua Wai Ke Za Zhi; 2000 Sep; 38(9):645-8. PubMed ID: 11832128
[TBL] [Abstract][Full Text] [Related]
29. Potential mechanisms linking gut microbiota and portal hypertension.
Baffy G
Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
[TBL] [Abstract][Full Text] [Related]
30. Risk Factors for a High Comprehensive Complication Index after Splenectomy Plus Pericardial Devascularization for Portal Hypertension.
Zhang Y; Lu H; Ji H; Li Y
Turk J Gastroenterol; 2023 Oct; 34(10):1041-1051. PubMed ID: 37603301
[TBL] [Abstract][Full Text] [Related]
31. Characteristics and Clinical Significance of Intestinal Microbiota in Patients with Chronic Hepatitis B Cirrhosis and Type 2 Diabetes Mellitus.
Sun X; Chi X; Zhao Y; Liu S; Xing H
J Diabetes Res; 2022; 2022():1826181. PubMed ID: 35601017
[TBL] [Abstract][Full Text] [Related]
32. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update.
Fukui H
Gut Liver; 2021 Sep; 15(5):666-676. PubMed ID: 33071239
[TBL] [Abstract][Full Text] [Related]
33. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis.
Maslennikov R; Ivashkin V; Efremova I; Poluektova E; Kudryavtseva A; Krasnov G
World J Gastroenterol; 2022 Mar; 28(10):1067-1077. PubMed ID: 35431497
[TBL] [Abstract][Full Text] [Related]
34. Gut microbiome dysbiosis and increased intestinal permeability in children with islet autoimmunity and type 1 diabetes: A prospective cohort study.
Harbison JE; Roth-Schulze AJ; Giles LC; Tran CD; Ngui KM; Penno MA; Thomson RL; Wentworth JM; Colman PG; Craig ME; Morahan G; Papenfuss AT; Barry SC; Harrison LC; Couper JJ
Pediatr Diabetes; 2019 Aug; 20(5):574-583. PubMed ID: 31081243
[TBL] [Abstract][Full Text] [Related]
35. Connection between the Gut Microbiome, Systemic Inflammation, Gut Permeability and FOXP3 Expression in Patients with Primary Sjögren's Syndrome.
Cano-Ortiz A; Laborda-Illanes A; Plaza-Andrades I; Membrillo Del Pozo A; Villarrubia Cuadrado A; Rodríguez Calvo de Mora M; Leiva-Gea I; Sanchez-Alcoholado L; Queipo-Ortuño MI
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228011
[TBL] [Abstract][Full Text] [Related]
36. Influence of hepatitis C virus eradication with direct-acting antivirals on the gut microbiota in patients with cirrhosis.
Ponziani FR; Putignani L; Paroni Sterbini F; Petito V; Picca A; Del Chierico F; Reddel S; Calvani R; Marzetti E; Sanguinetti M; Gasbarrini A; Pompili M
Aliment Pharmacol Ther; 2018 Dec; 48(11-12):1301-1311. PubMed ID: 30345704
[TBL] [Abstract][Full Text] [Related]
37. Structural and compositional segregation of the gut microbiota in HCV and liver cirrhotic patients: A clinical pilot study.
Ullah N; Kakakhel MA; Khan I; Gul Hilal M; Lajia Z; Bai Y; Sajjad W; Yuxi L; Ullah H; Almohaimeed HM; Al-Sarraj F; Assiri R; Aggad WS; Alharbi NA; Alshehri AM; Liu G; Sun H; Zhang C
Microb Pathog; 2022 Oct; 171():105739. PubMed ID: 36055570
[TBL] [Abstract][Full Text] [Related]
38. Effect of antiviral therapy on the survival and incidence of major complications in HBV-associated cirrhotic patients after splenectomy for hypersplenism and portal hypertension.
Tian N; Liu Z; Yang M; Li Z; Zhang G; Han Q; Li N; Zhu Q; Lv Y; Wang Y; Xing F
Virol J; 2012 Nov; 9():273. PubMed ID: 23158807
[TBL] [Abstract][Full Text] [Related]
39. Effect of Splenectomy on Serum Cytokine Profiles in Hepatitis B Virus-Related Cirrhosis Patients with Portal Hypertension.
Huang N; Ji F; Zhang S; Pu Y; Jiang A; Zhou R; Ji Y; Wei W; Yang J; Li Z
Viral Immunol; 2018 Jun; 31(5):371-378. PubMed ID: 29565232
[TBL] [Abstract][Full Text] [Related]
40. Targeting the gut-liver-immune axis to treat cirrhosis.
Tranah TH; Edwards LA; Schnabl B; Shawcross DL
Gut; 2021 May; 70(5):982-994. PubMed ID: 33060124
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
